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One of the most important representatives of the cytokine family is the transforming growth 
factor beta 1 (TGF beta 1). The purpose of the review is to study the biological role and clinical 
significance of TGF beta 1. Using PubMed databases, eLIBRARY, Google Scholar, keywords 
“cytokines”, “TGF beta 1” found 25,518 sources, 50 selected for analysis. TGF beta 1 is a poly-
valent cytokine first isolated from platelets in the 1990s.TGF beta 1 belongs to the family of 
dimeric polypeptides with a molecular weight of 25 kDa. The gene encoding TGF beta 1 is 
found in humans on chromosome 19. TGF beta 1 has a pleiotropic effect on the prolifera-
tion and differentiation of a wide range of cells, and therefore regulates many physiologic and 
pathophysiologic processes: immune response, apoptosis, fibrogenesis, and carcinogenesis. 
TGF beta 1 has an effect on almost all organs and tissues. TGF beta 1 is a key marker that can 
be used in the diagnosis of a number of diseases. It is necessary to further study the role of 
TGF beta 1 in the pathophysiologic mechanisms of various diseases, as well as in the develop-
ment of approaches to targeted therapy.
Keywords: transforming growth factor beta 1, TGF beta 1, cytokines, cell proliferation, im-
mune response, carcinogenesis, fibrogenesis.
Introduction
Cytokines are a group of polypeptide mediators that are involved in the regulation 
of normal physiological functions and the formation of protective reactions of the body. 
Their study began in the 1940s of the 20th century and by 2020, more than 200 cytokines 
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are already known [1]. New cytokines are discovered every year. By acting on the synthesis 
or action of cytokines, it is possible to prevent the development and treatment of various 
diseases.
One of the most important representatives of the cytokine family is the transforming 
growth factor beta 1 (TGF beta 1). It has a pleiotropic effect on the proliferation and dif-
ferentiation of a wide range of cells, and therefore regulates many physiological and patho-
physiological processes: immune response, apoptosis, fibrogenesis, and carcinogenesis in 
various organs [2–4].
The purpose of the REVIEW is to study the biological role and clinical significance 
of TGF beta 1.
Materials and methods
Using PubMed databases, eLIBRARY.ru, Google Scholar, keywords “cytokines”, “TGF 
beta 1” found 25,518 sources, 50 selected for analysis.
Results
In 1978, representatives of the TGF beta 1 family were first described. This group of 
cytokines got its name due to its ability to induce the transformation of the phenotype of 
normal cells in culture [5–7]. 
TGF beta  1  is a polyvalent cytokine first isolated from platelets in the 1990s.TGF 
beta 1 belongs to the family of dimeric polypeptides with a molecular weight of 25 kDa, 
and is widely represented in tissues. The gene encoding TGF beta 1 is located in humans 
on chromosome 19 [8–10]. The sources of TGF beta 1 are mainly monocytes and mac-
rophages, which contain it constantly, but secrete it only when activated. TGF beta 1 can 
also produce fibroblasts, endotheliocytes, neutrophils, eosinophils, mast cells, smooth 
muscle cells, as well as cells of many types of malignant tumors [11; 12].
TGF beta 1 has inhibitory activity in relation to T-and B-cell proliferation, as well as 
to maturation and activation of macrophages, i. e. it is an element of reverse regulation 
of the immune response, primarily the inflammatory response. TGF beta 1 inhibits the 
activity of NK cells, suppresses the cytotoxic activity of CD8 + lymphocytes, lymphokine-
activated killers, and blocks the production of cytokines and the secretion of certain im-
munoglobulins [13; 14]. It is a growth inhibitor in lymphoid, epithelial, and endothelial 
cells [15]. TGF beta 1 participates in repair processes in wounds, modulating inflamma-
tory processes [7]. Thus, TGF beta 1 has an impact on all organs and tissues.
A number of studies have studied the effects of TGF beta 1 on the kidneys. The role of 
TGF beta 1 in the formation of nephron structures, in particular, the wonderful network 
of the glomerulus of nephrons [11; 16]. 
Histone acetylation has been found to be an important modulator of gene expression 
in fibrosis. Fibrogenic cytokine TGF beta 1 affects the acetylation of histone 3 (H3) and its 
regulatory kinetics in renal myofibroblasts. Kidney fibroblasts of rats suffering from ure-
teral obstruction were treated with recombinant TGF beta 1 for 48 hours. TGF beta 1-in-
duced activation of myofibroblasts was accompanied by a decrease in total H3 acetylation. 
Thus, TGF beta 1 produces metabolic reprogramming in renal fibroblasts [17].
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The dynamics of the amount of TGF beta 1 in the blood serum of rats with experi-
mental chronic kidney disease was studied. It is shown that as this disease develops, there 
is an increase in serum concentration of TGF beta 1 until the 4th month, while at the 6th 
month there is a slight decrease in its level [18].
It is also noted that TGF beta 1 is a key mediator of diabetic nephropathy [19; 20].
TGF beta 1 participates in the formation of renal fibrosis by increasing the content of 
miR-21 via a Smad3-dependent mechanism [21]. 
Other organs are also affected by TGF beta 1. 
TGF beta 1 affects changes in the structure of the liver, so the use of immunohis-
tochemical diagnostics of the degree of TGF beta 1 expression is proposed to assess the 
degree of liver fibrosis [22].
Elevated levels of TGF beta 1 have been reported in endometriosis. It has been exper-
imentally proven that TGF beta 1 potentiates the adhesion of ectopic endometrial cells by 
enhancing the signal transmission axis of integrin and FAK, as well as migration through 
cadherin-mediated signal cascades of EMT and RHOGTPase [23].
It has been confirmed that TGF beta 1 contributes to the invasion of human gastric 
carcinoma cells SGC7901, causing autophagy [24].
The effect of TGF beta 1 on gum inflammation was studied. TGF beta 1 is an im-
munosuppressive cytokine that stimulates wound healing. An increased concentration 
of cytokine in an inflamed gum can counterbalance destructive inflammatory reac-
tions [25].
The high sensitivity, specificity, and accuracy of TGF beta  1 determination, along 
with the serum protein survivin, make them promising markers for early detection and 
follow-up of patients with retinoblastoma [26].
In relation to tumor cells, TGF beta 1 serves as a tumor suppressor (inhibition of cell 
proliferation, induction of apoptosis, reduction of telomerase activity) and a tumor pro-
moter (transdifferentiation, induction of angiogenesis, immunosuppression) [27].
Determination of TGF beta 1 in peripheral blood is recommended in the diagnosis of 
various diseases associated with chronic inflammatory process, such as Alzheimer’s disease, 
acquired immunodeficiency syndrome, Parkinson’s disease, glomerulonephritis, nephropa-
thy, diabetes, glomerulosclerosis, systemic lupus, autoimmune hepatitis, chronic fatigue syn-
drome, sepsis, stroke, various tissue tumors, etc. Elevated levels of TGF beta 1 are detected in 
patients with chronic fatigue and Guillain–Barre–Strohl syndromes [28–30]. 
The inverse correlation of TGF beta 1 level with disease activity is described in Kawa-
saki disease in patients with IgA deficiency [31]. 
It is proved that TGF beta 1 contributes to fibrotic processes, so its definition can be 
used for myelofibrosis and myeloid metaplasia. 
Increasing the serum level of TGF beta 1 in patients suffering from thrombocyto-
penic purpura implies its participation in hematopoiesis. 
It has been shown that determining the level of TGF beta 1 in serum and cerebro-
spinal fluid in multiple sclerosis is of great importance for monitoring remission and the 
active phase of the disease [29; 32]. 
TGF beta 1 plays an important role in bone marrow metabolism and can be consid-
ered a marker for osteoporosis [33]. 
TGF beta 1 may play a modulating role in tumor formation. In the early stages, 
TGF beta 1 proteins act, in some cases, as tumor suppressors. The definition of circu-
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lating TGF beta 1 may reflect different stages in solid tumors, such as cervical cancer. 
An increase in its level was detected in prostate cancer, bladder cancer, and liver cancer 
[28; 34; 35]. 
It was found that in patients with ischemic heart disease, serum levels of TGF beta 1 
were significantly higher than in healthy individuals. TGF beta 1 deficiency is one of the 
factors of atherosclerotic plaque destabilization [36; 37]. It has been shown that TGF 
beta 1 together with other cytokines, such as tumor necrosis factor and interleukin-1, is 
involved in the process of vascular remodeling [5; 38]. Development of acute coronary 
syndrome is accompanied by a significant increase in TGF beta 1 [36; 39]. In the early 
stages of myocardial infarction, TGF beta 1 can play an important role in the inflamma-
tory response by deactivating macrophages, suppressing endothelial chemokine recep-
tors, and synthesizing cytokines. At a later stage, it includes fibrogenetic pathways, induc-
ing deposition of the extracellular matrix, and can also contribute to the pathogenesis of 
left ventricular remodeling by activating fibroblasts and hypertrophy of the non-infarcted 
myocardium [36; 40; 41].
It is assumed that TGF beta 1 can cause thymus involution [42]. 
In recent years, it has been shown that an excess of TGF beta is of great importance in 
the formation of manifestations of hereditary connective tissue disorders. An increase in the 
concentration of this cytokine can be caused either by a mutation in the TGF beta recep-
tors, or by a violation of the activation control of the TGF beta molecule [43–45]. Structural 
abnormalities of the connective tissue framework of the heart were associated with activa-
tion of the TGF beta signaling pathway in patients with connective tissue dysplasia (mitral 
valve prolapse, aortic half-moon asymmetry) [46]. It has been shown that antibodies to TGF 
beta inhibit the development of Marfan syndrome in transgenic mice with a genetic model 
of this disease [47; 48]. Thus, a modern therapeutic strategy is being developed in the treat-
ment of connective tissue dysplasia, aimed at suppressing TGF beta 1. 
It is assumed that dysregulation of glucose metabolism, leading to the development of 
hypertension, may be due to excessive activity of TGF beta 1 [49]. Anti-TGF beta therapy 
is a promising direction in the treatment of acquired vascular diseases, such as angiopa-
thies associated with diabetes [50].
Conclusion
TGF beta 1 has an effect on almost all organs and tissues. TGF beta 1 is a key marker 
that can be used in the diagnosis of a number of diseases. It is necessary to further study 
the role of TGF beta 1 in the pathophysiological mechanisms of various diseases, as well 
as in the development of approaches to targeted therapy.
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